{"article_id": "OMI_q2_2021.txt", "article": ["in addition to the solid performance in our two reporting segments , our balance sheet remains strong , with net leverage at 1.8 times and total net debt of less than $ 1 billion .", "our strong second quarter gives us the confidence to affirm the range of our 2021 guidance for adjusted earnings per share and of $ 3.75 to $ 4.25 and adjusted ebitda of $ 450 million to $ 500 million as well as affirm our previously issued 2022 guidance .", "we 're maintaining our expectations for adjusted earnings per share in 2021 to be in a range of $ 3.75 to $ 4.25 and adjusted ebitda in the range of $ 450 million to $ 500 million .", "starting with the top line , revenue for the second quarter was $ 2.5 billion , compared to $ 1.8 billion for the prior year .", "this represents 38 % growth with strong performance in both of our segments .", "gross margin in the second quarter was 16.1 % , an improvement of 117 basis points over prior year due to revenue mix from higher margin sales in the global products segment and patient direct business , timing of the pass - through of glove costs and improved operating efficiency .", "also compared to q1 , gross margin was lower by nearly 300 basis points due to margin compression in gloves as anticipated and discussed last quarter .", "distribution , selling and administrative expense of $ 294 million in the current quarter was $ 52 million higher compared to the second quarter of 2020 .", "this performance coupled with the efficiency gains from enterprisewide continuous improvement led to adjusted operating income for the quarter of $ 116 million , which was $ 77 million higher or three times the same period last year .", "adjusted ebitda for the second quarter was $ 128 million , which increased by $ 76 million or over two times year - over - year .", "interest expense of $ 12 million in the second quarter was down 47 % or $ 10 million compared to last year , driven by lower debt levels and effective interest rates .", "on a gaap basis , income from continuing operations for the quarter was $ 66 million or $ 0.87 a share .", "adjusted net income for the second quarter was $ 80 million , which yielded an adjusted earnings per share for the quarter of $ 1.06 , which was over five times our performance from q2 of last year .", "the year - over - year foreign currency impact in the quarter was unfavorable by $ 0.02 .", "in the second quarter , the average diluted shares outstanding were 14.7 million higher year - over - year as a result of our equity offering in the fourth quarter of prior year and the impact of restricted shares for compensation .", "global solutions revenue of $ 1.98 billion was higher by $ 429 million or 28 % year - over - year .", "the segment experienced continued growth , driven by ongoing recovery in volumes associated with elective procedures of approximately $ 300 million along with higher sales of ppe as well as continued strong growth in our patient direct business .", "global solutions operating income was $ 18.5 million , which was $ 29 million higher than prior year as a result of higher volumes coupled with productivity and efficiency gains in our medical distribution business .", "in our global products segment , net revenue in the second quarter was $ 689 million , compared to $ 370 million last year , an increase of 86 % , which was led by higher s&ip sales particularly ppe volume as we benefited from our previous investments to expand capacity and the previously discussed impact of passing through higher acquisition costs of approximately $ 200 million .", "operating income for the global products segment was $ 95 million , an increase of 84 % versus $ 52 million in the second quarter last year .", "total net debt at the end of the second quarter was $ 964 million and total net leverage was 1.8 times trailing 12 - months adjusted ebitda .", "we now expect the full year top line impact of glove cost pass - through to be in the range of $ 675 million to $ 725 million .", "guidance for adjusted earnings per share is based on 75.5 million shares outstanding .", "even with the 6 % increase in shares and new inflationary headwinds , we are confirming our outlook for 2021 , 2022 and targets for 2026 ."], "summary_gold": "sees fy adjusted earnings per share $ 3.75 to $ 4.25 .<q>q2 gaap earnings per share $ 0.87 .<q>qtrly adjusted earnings per share $ 1.06 .<q>affirms previously announced 2021 and 2022 guidance .", "summary_pred": "adjusted net income for the second quarter was $ 80 million , which yielded an adjusted earnings per share for the quarter of $ 1.06 , which was over five times our performance from q2 of last year .<q>we now expect the full year top line impact of glove cost pass - through to be in the range of $ 675 million to $ 725 million .<q>even with the 6 % increase in shares and new inflationary headwinds , we are confirming our outlook for 2021 , 2022 and targets for 2026 .<q>this represents 38 % growth with strong performance in both of our segments .<q>the year - over - year foreign currency impact in the quarter was unfavorable by $ 0.02 .<q>in addition to the solid performance in our two reporting segments , our balance sheet remains strong , with net leverage at 1.8 times and total net debt of less than $ 1 billion .<q>also compared to q1 , gross margin was lower by nearly 300 basis points due to margin compression in gloves as anticipated and discussed last quarter .<q>the segment experienced continued growth , driven by ongoing recovery in volumes associated with elective procedures of approximately $ 300 million along with higher sales of ppe as well as continued strong growth in our patient direct business .", "len_article": 24, "len_summary_gold": 4, "len_summary_pred": 8, "len_sent_scores": 24}